Quince Therapeutics has announced a significant strategic move with its acquisition of Orphai Therapeutics, a clinical-stage biotechnology company. This transaction brings Orphai's promising lead candidate, LAM-001, for rare pulmonary diseases into Quince's pipeline. The acquisition is supported by a concurrent private placement financing expected to raise up to $187 million, positioning the company for substantial growth and clinical advancement.
A Transformative Acquisition and Financing Deal
The acquisition was structured as a stock-for-stock merger, integrating Orphai's assets and team into Quince's operations. Concurrent with this deal, Quince secured a major private placement led by Balyasny Asset Management, with participation from numerous leading healthcare investors. This financing provides $115 million in upfront proceeds, with the potential for an additional $72 million upon the exercise of accompanying warrants.
The substantial capital infusion is expected to extend Quince's operational runway through the end of 2028. This financial stability will support the advancement of LAM-001 through several critical clinical milestones over the next few years. Dirk Thye, CEO of Quince, stated the transaction reinforces the company's strategy to build a focused, high-impact biotechnology firm that delivers value to patients and stockholders.
Spotlight on Lead Candidate LAM-001
At the center of the acquisition is LAM-001, a proprietary, once-daily inhaled formulation of sirolimus, also known as rapamycin. The drug is designed to inhibit the mTOR pathway, which plays a key role in the proliferation of pulmonary arterial smooth muscle cells. By targeting this pathway, LAM-001 has the potential to be a disease-modifying agent for several severe pulmonary conditions.
The formulation is engineered to enhance drug delivery directly to the lungs while reducing systemic exposure, offering a promising therapeutic profile. Its mechanism also shows direct anti-fibrotic activity, making it particularly relevant for conditions like pulmonary hypertension associated with interstitial lung disease (PH-ILD). This dual action addresses both vascular remodeling and progressive fibrosis, which are hallmarks of the disease.
Charting the Clinical Path Forward
Quince has outlined a clear clinical development timeline for LAM-001 across multiple indications with significant unmet medical needs. The company recently presented compelling Phase 2a data for PH-ILD at the American Thoracic Society conference. Based on these results, a Phase 2b trial in PH-ILD is planned to begin in mid-2026, with data anticipated in the first quarter of 2028.
Further clinical studies are also underway or planned for other rare pulmonary diseases. A Phase 2 trial in bronchiolitis obliterans syndrome (BOS) is expected to yield data in the first quarter of 2027. Additionally, Quince plans to initiate a Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH) in late 2026, with results expected in the fourth quarter of 2028.
New Corporate Structure and Vision
Following the transaction's completion, the company will have a new ownership structure. Existing Quince equity holders will own approximately 6.9% of the combined entity, while former Orphai equity holders will hold 31.9%. Investors participating in the private placement will own the majority, with approximately 61.2% of the company's common stock on a fully-diluted basis.
Brigette Roberts, former CEO of Orphai Therapeutics and now Chief Corporate Affairs Officer of Quince, expressed enthusiasm for the program's future. She highlighted the strong positive reception from the medical community regarding the initial data for LAM-001. The combined expertise and strengthened balance sheet are set to accelerate the development of this potentially transformative therapy for patients with progressive lung diseases.
The acquisition of Orphai Therapeutics and the concurrent financing mark a pivotal moment for Quince Therapeutics. This strategic consolidation creates a well-funded entity focused on advancing a late-stage clinical asset for rare pulmonary diseases. With a clear roadmap and capital to execute its plans through 2028, Quince is strongly positioned to make a meaningful impact on patient care and deliver significant stockholder value.